SanaCurrents on topline data from the LUM-201 trials to treat hormone deficiency
Lumos Pharma, Inc. (NASDAQ:LUMO) Probability Sentiment SUMMARY Lumos Pharma, Inc. (NASDAQ:LUMO) went public in 2019 [...]
SanaCurrents on ImmunityBio’s (IBRX) superagonist to treat NMIBC
Immunitybio, Inc. (NASDAQ:IBRX) Probability Sentiment SUMMARY Backed by biotech billionaire Patrick Soon-Shiong, ImmunityBio, Inc. (NASDAQ:IBRX) [...]
SanaCurrents’ Sentiment for PDUFA decision on Krystal’s (KRYS) gene therapy B-VEC
$KYRS Probability Sentiment SUMMARY Krystal Biotech’s B-VEC treatment for the rare skin disease dystrophic epidermolysis [...]
SanaCurrents on Eiger’s (EIGR) late stage combinations to treat hepatitis delta virus (HDV)
Eiger Biopharmaceuticals, Inc. (NASDAQ:EIGR) Probability Sentiment SUMMARY Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) seeks to carve out [...]
SanaCurrents on Lexicon’s (LXRX) sotagliflozin challenge to treat heart failure
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Probability Sentiment SUMMARY Once a biopharma highflyer when it was known [...]
SanaCurrents on Affimed’s (AFMD) immunotherapy in Peripheral T-cell lymphoma (PTCL)
Affimed N.v. (NASDAQ:AFMD) Probability Sentiment SUMMARY Peripheral T-cell lymphoma (PTCL) strikes 1 in 100,000 Americans [...]
SanaCurrents on Vaxcyte (PCVX) new pneumonia vaccine
Vaxcyte, Inc. (NASDAQ:PCVX) Probability Sentiment SUMMARY Vaccines once were considered poor performing units inside Big [...]
SanaCurrents on FDA decision for Forma’s (FMTX) rare leukemia drug
Forma Therapeutics Holdings, In (NASDAQ:FMTX) Probability Sentiment SUMMARY Armed with a precision oncology approach and [...]